Ascendis Pharma A/S reports developments as a global biopharmaceutical company applying its TransCon technology platform to new therapies in endocrinology, rare disease and oncology. News commonly centers on TransCon CNP, also known as navepegritide, including YUVIWEL for pediatric achondroplasia, as well as TransCon hGH combination data and growth-disorder clinical programs.
Recurring company updates also include financial results and business updates, U.S. regulatory and commercialization milestones, patient-access programs, and capital-structure actions such as convertible senior note activity. Corporate news also documents the completed transition from American Depositary Shares to ordinary shares trading on Nasdaq under ASND.
Ascendis Pharma (Nasdaq: ASND) will report first quarter 2026 financial results and provide a business update on May 7, 2026, before U.S. market open. The company will host a conference call and live webcast on May 7, 2026 at 8:00 a.m. ET.
Registration links and a live-webcast link will be available via the Investors & News section of the Ascendis Pharma website. A replay will be posted and available for 30 days after the event.
Ascendis Pharma (Nasdaq: ASND) called for redemption of all $575.0 million aggregate principal amount of its 2.25% Convertible Senior Notes due 2028, with a redemption date of May 6, 2026.
Holders may convert through 5:00 p.m. NY on May 4, 2026; conversion rate is 6.0118 shares per $1,000, increased to 6.3232 shares during the Make-Whole Conversion Period, making up to 3,635,840 ordinary shares issuable if converted.
Ascendis Pharma (Nasdaq: ASND) commenced trading of its ordinary shares on the Nasdaq Global Select Market on April 20, 2026, replacing its American Depositary Shares (ADSs).
The ordinary shares trade under the same ticker ASND, CUSIP K08588103 and ISIN DK0060606333. The company completed a mandatory exchange of all outstanding ADSs for ordinary shares, with the last ADS trading day on Nasdaq on April 17, 2026. A FAQ is available on the company investor website for details on the exchange and listing.
Ascendis Pharma (Nasdaq: ASND) will list its ordinary shares directly on The Nasdaq Global Select Market, effective at the open on April 20, 2026. All outstanding ADSs will be exchanged 1-for-1 for ordinary shares, which will trade under the existing ticker ASND.
The ordinary shares will use new identifiers: CUSIP K08588103 and ISIN DK0060606333. The company said the simplified listing aims to broaden investor access, potentially support index inclusion, and enhance institutional ownership and liquidity. A FAQ will be posted on the company's investor website.
Ascendis Pharma (Nasdaq: ASND) reported Week 52 COACH Phase 2 data showing that once-weekly TransCon hGH added to once-weekly TransCon CNP accelerated benefits beyond linear growth in children with achondroplasia. Key results: arm span Z-score +1.02 (treatment-naïve) and +0.66 (treated); arm gains +9.4 cm and +7.9 cm. Spinal L1-L5 IPD changes +1.7 mm (naïve) and +1.1 mm (treated) vs +0.6 mm with monotherapy. Tibial femoral angle improved -3.0° (combination) vs -1.3° (monotherapy); TFA Z-score -0.86 vs -0.47. TransCon CNP (YUVIWEL) received FDA approval Feb 2026; TransCon hGH (SKYTROFA) is approved for GH deficiency but investigational in achondroplasia.
Ascendis (Nasdaq: ASND) announced that YUVIWEL (navepegritide) received U.S. FDA orphan drug exclusivity and is now commercially available in the United States.
The FDA approved YUVIWEL on Feb 27, 2026 under accelerated approval to increase linear growth in children ≥2 years with achondroplasia with open epiphyses; orphan exclusivity runs through Feb 27, 2033. Ascendis reports revenue recognition following approval of first patients and therapy initiation and has launched the Ascendis Signature Access Program (A.S.A.P.) to support access and reimbursement.
Ascendis Pharma (Nasdaq: ASND) reported Week 52 topline results from New InsiGHTS, a Phase 2 randomized, open-label trial in 49 prepubertal children with Turner syndrome.
TransCon hGH (lonapegsomatropin) produced an LS mean annualized height velocity of 9.05 cm/year, versus 9.04 cm/year for daily somatropin, with comparable safety and no SCFE occurrences through up to 143 weeks follow-up.
Ascendis Pharma (Nasdaq: ASND) shared two-year data from the pivotal ApproaCH Trial showing once-weekly TransCon CNP (navepegritide) sustained linear growth benefits through Week 104 and further improved body proportionality in children with achondroplasia.
Key facts: randomized trial in 84 children (2–11 years), upper-to-lower segment ratio improved from -0.04 at Week 52 to -0.10 at Week 104, 80 of 84 completed the trial, FDA approved YUVIWEL in Feb 2026, EMA decision expected Q4 2026, tolerability was generally favorable with no symptomatic hypotension and injection-site reactions at 0.35 per person-year.
Ascendis Pharma (Nasdaq: ASND) will participate in a virtual fireside chat at the TD Cowen 46th Annual Health Care Conference on March 2, 2026 at 11:10 a.m. ET.
A live webcast and a replay available for 30 days will be accessible via the companys Investors & News website at investors.ascendispharma.com.
Ascendis Pharma (Nasdaq: ASND) announced FDA accelerated approval of YUVIWEL (navepegritide), the first and only once-weekly therapy to provide continuous systemic exposure to CNP for children with achondroplasia aged 2 years and older with open epiphyses. Continued approval may require confirmatory trials.
Commercial availability is expected in early Q2 2026 and a Rare Pediatric Disease Priority Review Voucher was issued.